spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  fungal infection 

 HSMN NewsFeed - 13 Apr 2026
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 11 Mar 2024
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(R) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Mar 2024
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar(R) Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector
Devices Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 13 Jan 2022
PANTHERx Rare(R) Selected by Xeris Pharmaceuticals to Distribute Recorlev(R) (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing's Syndrome
Biopharmaceuticals Distribution
 HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 25 Sep 2020
Study Reveals Blood-Based Host Response Test Can Accurately Predict Respiratory Viral Infection in Pre-Symptomatic Patients
Diagnostics
 HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 15 Jun 2020
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jun 2020
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2020
Amplyx Pharmaceuticals Expands Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Feb 2020
Karius Secures $165 Million In Series B Funding Led By SoftBank Vision Fund 2
Diagnostics Venture Capital
 HSMN NewsFeed - 9 Dec 2019
Moberg Pharma Meets Primary Endpoint for MOB-015 in a Phase 3 Study for the Treatment of Onychomycosis
Biopharmaceuticals
 HSMN NewsFeed - 25 Nov 2019
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Oct 2019
Eyevance Pharmaceuticals Acquires TOBRADEX(R) ST and NATACYN(R)
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 14 Jun 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2019
FDA Approves SORILUX(R) for Adolescent Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 8 Apr 2019
F2G Appoints Dr. Patrick Vink as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2019
Bausch & Lomb Announces the U.S. Launch of LOTEMAX(R) SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% for the Treatment of Postoperative Inflammation and Pain Following Ocular Surgery
Biopharmaceuticals Ophthalmology Surgery Product Launch
 HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 1 May 2018
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Mar 2018
Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch
 HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 28 Sep 2017
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 2 Aug 2017
Amplyx Pharmaceuticals Raises $67 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2017
BlackThorn Therapeutics Names Biotech Industry Veteran Gregory Vontz as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2016
Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2016
Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 1 Feb 2016
Dr. Reddy’s Laboratories Receives USFDA Tentative Approval for Zenavod(TM) (doxycycline) Capsules, 40 mg for the Treatment of Rosacea in Adults
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 6 Jan 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2015
Viamet Appoints Dr. Volker Herrmann as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Nov 2015
Amplyx Pharmaceuticals Secures $40.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Oct 2015
Viamet Appoints Dr. Oren Cohen as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2015
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 11 Feb 2015
Cidara Therapeutics Completes $42 Million Private Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Feb 2015
SCYNEXIS Names Marco Taglietti, M.D., Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2015
Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Dec 2014
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 21 Oct 2014
Viamet Announces $60 Million Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Jul 2014
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States
Biopharmaceuticals Dermatology Distribution
 HSMN NewsFeed - 30 Jun 2014
Cidara Therapeutics Completes $32 Million Series A Financing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2014
SCYNEXIS Appoints Carole Sable, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2014
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
Biopharmaceuticals Distribution
 HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Nov 2012
Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2012
Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA(R) (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Jul 2012
Sandoz completes acquisition of Fougera Pharmaceuticals, positioning Sandoz as #1 in generic dermatology globally
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
Abbott Announces 10-Year Data Evaluating HUMIRA(R) (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 16 Dec 2011
Valeant Announces Successful Results From Phase III Onychomycosis Trials
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2011
TOPICA Names Dr. Amir Tavakkol Senior Vice President of Clinical Development and Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Nov 2011
Viamet Pharmaceuticals Appoints Former Novartis Executive Marc Rudoltz, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 4 Apr 2011
Anacor Pharmaceuticals Appoints William J. Rieflin to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Oct 2010
Kadmon Pharmaceuticals Acquires Three Rivers Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Oct 2010
Anacor Pharmaceuticals Appoints Geoffrey M. Parker as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2010
Basilea's Toctino(R) receives marketing authorization in Italy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Feb 2010
TOPICA Names Mark W. Davis Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2009
Safeguard Scientifics Leads $17.4 Million Series B Financing for Quinnova Pharmaceuticals
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Aug 2009
Medical Industry Veteran Bob Katz to Lead Newly Established PinPointe USA, Inc. as CEO
Devices Personnel
 HSMN NewsFeed - 22 Jul 2009
GlaxoSmithKline Completes Acquisition of Stiefel
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2009
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Biopharmaceuticals
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Apr 2009
GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 11 Feb 2009
HemCon Medical Technologies, Inc. Announces Further Successful Results from Live Nail Infection Anti-Fungal Study
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2009
Lytix Closes USD 10.4 Million Funding Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Jan 2009
Nomir Medical Announces Second FDA 510(k) Clearance of its Noveon(R) Dual-Wavelength Device
Devices FDA
 HSMN NewsFeed - 6 Jan 2009
Anacor Raises $50 Million in Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Dec 2008
Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2008
Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 28 Jul 2008
Barrier Therapeutics Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Jul 2008
Stiefel Laboratories, Inc. Commences Tender Offer to Acquire Barrier Therapeutics, Inc.
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 23 Jun 2008
Barrier Therapeutics, Inc. and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 23 Jun 2008
Barrier Therapeutics to Merge Into Stiefel Laboratories
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2008
Barrier Therapeutics Announces Agreement with Procter & Gamble to Market Xolegel (ketoconazole, USP) Gel, 2 Percent With Head & Shoulders Shampoo as Xolegel Duo
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 May 2008
Nomir Medical Initiates Pivotal Trial of its Noveon(R) Dual Wave Length Device for the Treatment of Onychomycosis
Devices
 HSMN NewsFeed - 13 May 2008
Skinvisible Signs Licensing Agreement for Two Acne Formulations
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 7 May 2008
Astellas' Mycamine(R) (micafungin) Licensed for Use in Europe to Treat Serious Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Mar 2008
FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Mar 2008
Immtech Announces Update on Business Operations
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Feb 2008
FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jan 2008
FDA Approves Additional Indication for Astellas' MYCAMINE(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Dec 2007
Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2007
BioAlliance Pharma Acquires the European Commercialization Rights to Pafuramidine for the Treatment of Pneumocystis Carinii Pneumonia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Oct 2007
Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2007
Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2007
Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Sep 2007
Barrier Therapeutics Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Hyphanox(TM) for Onychomycosis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Sep 2007
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Study Presented on Use of CANCIDAS(R) (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2007
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2007
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
Barrier Therapeutics Introduces New Xolegel Duo(TM) Offering at the American Academy of Dermatology (AAD) Summer Academy Meeting 2007
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Jul 2007
Elusys Appoints New Chairman of the Board and a Vice President of Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jul 2007
Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Jun 2007
Elusys Names Jeremy D. Middleton Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2007
Anacor Names Paulette Dillon as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2007
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 12 Jun 2007
Immtech and Par Enter Licensing Agreement on Pafuramidine for Treatment of Pneumocystis Pneumonia
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
Ranbaxy Expands its Presence in the U.S. Dermatology Market Through the Acquisition of 13 Brands from Bristol Myers Squibb
Biopharmaceuticals Dermatology Acquisitions
 HSMN NewsFeed - 16 May 2007
Barrier Therapeutics Appoints Dr. Braham Shroot, Dermatology Expert, as New Chief Scientific Officer
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 3 May 2007
Barrier Therapeutics Receives FDA Approval for Solagé(R) Topical Solution Labeling Expansion
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 30 Apr 2007
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
Oncology
 HSMN NewsFeed - 27 Apr 2007
INVEGA(R) Receives Positive Opinion From European Committee for Human Medicinal Products for Treatment of Schizophrenia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Apr 2007
Indevus and Valera Announce Completion of Merger
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Apr 2007
Media Advisory: Voluntary Drug Recall - Ortho-McNeil Pharmaceutical, Inc. Issues a Nationwide Recall of GRIFULVIN V(R)/Griseofulvin Oral Suspension
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 27 Mar 2007
Barrier Therapeutics Announces Azoline (Pramiconazole) Dose Ranging Study in Tinea Versicolor Meets Primary and Secondary Endpoints
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Mar 2007
Indevus Reports That Interim Review of NEBIDO(R) Phase III Data Indicates Trial Is Likely to Meet Primary Endpoints
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 20 Mar 2007
New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2007
Barrier Therapeutics Receives Regulatory Approval to Market Xolegel(TM) in Canada
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 6 Mar 2007
Barrier Therapeutics Announces Agreement to Co-Promote Vusion(TM) Ointment to Pediatricians in the United States
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Feb 2007
BDSI Announces FDA Acceptance of Bioral(R) Amphotericin IND
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 2 Feb 2007
Anacor Signs Worldwide Exclusive License Agreement With Schering-Plough for AN2690, a New Topical Anti-Fungal Treatment
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Jan 2007
NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2007
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Alkermes and Indevus Announce Joint Collaboration to Develop Inhaled Formulation of Trospium Chloride for the Treatment of COPD
Biopharmaceuticals
 HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Dec 2006
Basilea Announces Start of Phase III Program for Isavuconazole, Its Third Investigational Drug to Reach Pivotal Trials
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
Basilea to Co-Promote Ceftobiprole
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce Out-licensing of Aminocandin Anti-fungal
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Nov 2006
US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 9 Nov 2006
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Nov 2006
Indevus Announces Licensing and Manufacturing Pact for SANCTURA XR(TM) With Madaus GmbH
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Oct 2006
Pfizer Assists World Health Organization in Search for New Treatments Against Diseases of the Developing World
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Treatment of Oropharyngeal Candidiasis (OPC)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Oct 2006
Indevus Announces the Finalization of Supply Agreement with Schering AG, Germany for NEBIDO(R)
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2006
Indevus Pharmaceuticals Announces Appointment of Thomas Farb as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2006
BioAlliance Pharma Receives Marketing Authorisation for Its First Product, Loramyc(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Oct 2006
Indevus Announces Submission of New Drug Application Seeking Approval for SANCTURA XR to Treat Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 11 Oct 2006
Immtech Pharmaceuticals Announces Antimicrobial Pipeline Progress
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
New Data Confirming Broad Spectrum of Basilea's Late-Stage Antifungal, BAL8557, Presented at the ICAAC Conference
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2006
Indevus Announces Clinical and Regulatory Plans for Pagoclone
Biopharmaceuticals
 HSMN NewsFeed - 22 Sep 2006
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Sep 2006
Alcon Licenses Novel Anti-Infective Compounds for Eye, Ear and Sinus Infections from NovaCal
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 18 Sep 2006
European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 18 Sep 2006
Anacor Expands Clinical Development Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jul 2006
Elusys Therapeutics Completes $23 Million Series D Venture Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Jul 2006
Indevus Announces Positive Data from Second Phase III Trial for SANCTURA XR(TM) in Overactive Bladder
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Jun 2006
New Phase III Data Demonstrate That Abbott's HUMIRA(R) (Adalimumab) Sustained Reduction in Signs and Symptoms Through One Year in Patients With Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Indevus Announces Promising Phase II Data for Pagoclone In Stuttering
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2006
Medicis Announces FDA Approval of SOLODYN -- minocycline HCl, USP -- Extended Release Tablets
Biopharmaceuticals Dermatology FDA
Return to NewsFeed  

 Additional items found! 212

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 212 additional stories matching:
fungal infection
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!